Drug Profile
SSR 101010
Alternative Names: SSR101010Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antidepressants; Anxiolytics
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 11 Feb 2009 Discontinued - Phase-I for Anxiety disorders in USA (unspecified route)
- 11 Feb 2009 Discontinued - Phase-I for Depression in USA (unspecified route)